ClinicalTrials.gg
CompletedNCT02481505Updated May 18, 2021Results posted

Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration.

A Phase 2 interventional study of Chloroprocaine HCl 1% in Short Duration Lower Limb Surgery Via Spinal Anaesthesia, sponsored by Sintetica SA. Completed at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by Sintetica SA · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study evaluate the effect of 3 doses of Chloroprocaine HCl 1% (30, 40 and 50 mg) for spinal anaesthesia in adult patients undergoing short duration elective surgery of the lower limb. Patients undergoing elective short-duration lower limb surgery will be randomised into 3 treatment groups (15 patients per group) to receive one of the 3 single doses of Chloroprocaine HCl 1%, i.e. either D1, D2 or D3, via intrathecal injection.

Read the detailed description

To evaluate the efficacy of the three Chloroprocaine HCl 1% doses (i.e. D1, D2 and D3) in terms of time to complete regression of spinal block (i.e. end of anaesthesia)

02

Conditions studied

  • Short Duration Lower Limb Surgery Via Spinal Anaesthesia
03

In context

Lead sponsor

Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex, age and surgery: male/female patients, 18-65 years old, scheduled for short duration (less than 40 min) lower limb surgery requiring ≥ T12 metameric level of sensory block
  2. (BMI): 18 - 32 kg/m2 inclusive
  3. : I-II
  4. : signed written informed consent before inclusion in the study 5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study.

Exclusion criteria

Exclusion Criteria:

  1. Physical findings: abnormal physical findings which could interfere with the objectives of the study. to spinal anaesthesia. History of neuromuscular diseases to the lower extremities
  2. : III-V
  3. Further anaesthesia: patients expected to require further anaesthesia
  4. Allergy: ascertained or presumptive to the active principle and/or formulations ingredients; ascertained or presumptive hypersensitivity to the ester type and major anaesthetics
  5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study; ascertained psychiatric and neurological diseases, sepsis, blood coagulation disorders, severe cardiopulmonary disease, thyroid disease, diabetes or other neuropathies.
  6. Investigative drug studies: participation in the evaluation of any product for 3 months before this study, calculated from the first day of the month following the last visit of the previous study
  7. Drug, alcohol: history of drug or alcohol abuse
  8. Blood donation: blood donations in the 3 months before this study
  9. Pregnancy and lactation: missing or positive pregnancy test at screening, pregnant or lactating women
  10. Chronic pain syndromes: patients with chronic pain syndromes (taking opioids, antidepressants, anticonvulsant agents or chronic analgesic therapy) 11. Medications: medication known to interfere with the extent of spinal blocks for 2 weeks before the start of the study. Hormonal for females are allowed.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    3 mL Chloroprocaine HCl 1%

    Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)

    Drug: Chloroprocaine HCl 1%

  • Experimental
    4 mL Chloroprocaine HCl 1%

    Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)

    Drug: Chloroprocaine HCl 1%

  • Experimental
    5 mL Chloroprocaine HCl 1%

    Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)

    Drug: Chloroprocaine HCl 1%

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Regression of Spinal Block

    When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

    Time frame: Up to 5 hours after regression of two dermatomers

Secondary outcomes

  1. Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)

    Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.

    Time frame: Up to 40 min after spinal injection

  2. Time to Onset of Motor Block

    Time period from spinal injection (time 0 h) to achievement of motor block

    Time frame: Up to 40 min after spinal injection

  3. Time to Readiness for Surgery

    Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12

    Time frame: Up to 40 min after spinal injection

  4. Time to Regression of Spinal Block

    Time frame: Up to 1 h and 40 min after readiness for surgery

  5. Time to Resolution of Sensory Block to S1(Min)

    Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1

    Time frame: Up to 5 h after regression of two dermatomers

  6. Time to Resolution of Motor Block

    Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

    Time frame: Up to 5 h after regression of two dermatomers

  7. Time to Unassisted Ambulation

    Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted

    Time frame: Up to 5 h after regression of two dermatomers

  8. Sensory Block Metameric Level

    Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1

    Time frame: Up to 5 h after regression of two dermatomers

  9. Maximum Level of Sensory Block

    Maximum metameric level of sensory block (decreased or absent sensation) achieved

    Time frame: Up to 1 h and 40 min after readiness for surgery

  10. Time to Maximum Level of Sensory Block

    Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)

    Time frame: Up to 1 h and 40 min after readiness for surgery

  11. Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block

    Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block

    Time frame: Up to 5 h after regression of two dermatomers

  12. Time to Eligibility for Home Discharge

    Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time

    Time frame: Expected up to 24 hrs post surgery

  13. Time to First Spontaneous Urine Voiding

    Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

    Time frame: Expected up to 24 hrs post surgery

  14. Time to First Post-operative Analgesia

    Time from spinal injection (time 0 h) to first post-operative analgesia

    Time frame: Expected up to 24 hrs post surgery

  15. Time to Administration of Rescue Anaesthesia or Rescue Analgesia

    Time frame: Expected up to 24 hrs post surgery

  16. Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma

    Time frame: at pre-dose, 5, 10, 30 and 60 min after spinal puncture

  17. Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine

    Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

    Time frame: at the time of first urine voiding post surgery

  18. Treatment-emergent Adverse Events (TEAEs)

    All AEs occurring or worsening after the dose of IMP

    Time frame: Up to Day 6 +/- 1 after spinal puncture

  19. Transient Neurological Symptoms (TNS)

    Time frame: Up to Day 6 +/- 1 after spinal puncture

  20. Pain Assessment at the Site of Injection and at the Site of Surgery

    Number of patients with pain at the site of injection and at the site of surgery

    Time frame: Up to Day 6 +/- 1 after spinal puncture

  21. Heart Rate

    The following normal ranges Heart Rate parameters will be used: 50-90 beats/min

    Time frame: Expected up to 24 hrs post surgery

  22. Blood Pressure

    The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg

    Time frame: Expected up to 24 hrs post surgery

  23. SpO2

    The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%

    Time frame: Expected up to 24 hrs post surgery

07

Results

Posted May 18, 2021

Participant flow

Participant flow — Overall Study
Milestone3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Started151515
Completed151515
Not completed000

Outcome measures

PrimaryTime to Regression of Spinal Block

When Bromage score returns to 0 and sensitive perception returns to S1 To evaluate the efficacy of the three Chloroprocaine HCI 1% doses (i.e. 30 mg, 40 mg e 50 mg) in terms of time to complete regression of spinal block (i.e. end of anaesthesia) Bromage Score is comprised between 1 and 4 (1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

Time frame:
Up to 5 hours after regression of two dermatomers
Reported as:
Mean · minutes
Time to Regression of Spinal Block
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Regression of Spinal Block40.8 ± 12.139.4 ± 12.541.5 ± 13.9
SecondaryTime to Onset of Sensory Block (Corresponding to Readiness for Surgery)

Time period from spinal injection (time 0 h) to achievement of sensory block The evolution of both sensory and motor blocks, including sensory block metameric level, will be evaluated every 2 min until readiness for surgery, every 5 min until the maximum level is reached (two consecutive observations with the same level of sensory block) and then every 5 min until regression of two dermatomers with respect to the maximum level of sensory block.

Time frame:
Up to 40 min after spinal injection
Reported as:
Mean · minutes
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)5.4 ± 36.6 ± 3.44.8 ± 2
SecondaryTime to Onset of Motor Block

Time period from spinal injection (time 0 h) to achievement of motor block

Time frame:
Up to 40 min after spinal injection
Reported as:
Mean · minutes
Time to Onset of Motor Block
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Onset of Motor Block6.3 ± 3.26 ± 3.34.4 ± 2.3
SecondaryTime to Readiness for Surgery

Time period from completion of spinal injection (time 0 h) to achievement of sensory and motor block adequate for surgery, i.e. loss of Pinprick sensation and Bromage's score ≥ 2 at the required metameric level ≥ T12

Time frame:
Up to 40 min after spinal injection
Reported as:
Mean · minutes
Time to Readiness for Surgery
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Readiness for Surgery8 ± 4.17.9 ± 4.75.3 ± 2
SecondaryTime to Regression of Spinal Block
Time frame:
Up to 1 h and 40 min after readiness for surgery
Reported as:
Mean · hours
Time to Regression of Spinal Block
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Regression of Spinal Block1.761 ± 0.3482.127 ± 0.4572.229 ± 0.379
SecondaryTime to Resolution of Sensory Block to S1(Min)

Time period from spinal injection (time 0 h) to the time when sensitive perception has returned to S1

Time frame:
Up to 5 h after regression of two dermatomers
Reported as:
Mean · hours
Time to Resolution of Sensory Block to S1(Min)
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Resolution of Sensory Block to S1(Min)1.761 ± 0.3482.127 ± 0.4572.195 ± 0.386
SecondaryTime to Resolution of Motor Block

Time period from spinal injection (time 0 h) to the time when the Bromage score has returned to 0 (Bromage Scale comprises from 1 to 4, where 1 equals Free movement of legs and feet while 4 stands for Unable to move legs or feet)

Time frame:
Up to 5 h after regression of two dermatomers
Reported as:
Mean · hours
Time to Resolution of Motor Block
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Resolution of Motor Block2.662 ± 0.7893.361 ± 1.1203.213 ± 0.856
SecondaryTime to Unassisted Ambulation

Time period from spinal injection (time 0 h) to the time when the patient can walk unassisted

Time frame:
Up to 5 h after regression of two dermatomers
Reported as:
Mean · hours
Time to Unassisted Ambulation
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Unassisted Ambulation2.662 ± 0.7893.361 ± 1.1203.213 ± 0.856
SecondarySensory Block Metameric Level

Metameric level of sensory block assessed from spinal injection (time 0 h) until regression of sensory block to S1

Time frame:
Up to 5 h after regression of two dermatomers
Reported as:
Number · participants
Sensory Block Metameric Level
participants3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
T2022
T3101
T4321
T6014
T7101
T8332
T10313
T12351
L1110
SecondaryMaximum Level of Sensory Block

Maximum metameric level of sensory block (decreased or absent sensation) achieved

Time frame:
Up to 1 h and 40 min after readiness for surgery
Reported as:
Number · participants
Maximum Level of Sensory Block
participants3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
T2022
T3101
T4321
T6014
T7101
T8332
T10313
T12351
L1110
SecondaryTime to Maximum Level of Sensory Block

Time period from spinal injection (Tsp; time 0 h) to the time when the maximum metameric level of sensory block is achieved (consider the time of the first of the two consecutive observations with the same level of sensory block)

Time frame:
Up to 1 h and 40 min after readiness for surgery
Reported as:
Mean · minutes
Time to Maximum Level of Sensory Block
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Maximum Level of Sensory Block0.224 ± 0.140.235 ± 0.0770.234 ± 0.098
SecondaryTime to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block

Time period from spinal injection (time 0 h) to the time when the sensory block decrease of two dermatomers with respect to the maximum level of sensory block

Time frame:
Up to 5 h after regression of two dermatomers
Reported as:
Mean · hours
Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Regression of Two Dermatomers With Respect to the Maximum Level of Sensory Block0.687 ± 0.3610.851 ± 0.4680.695 ± 0.290
SecondaryTime to Eligibility for Home Discharge

Time period from spinal injection (time 0 h) to the time when the criteria from discharge are met, even if according to the hospital procedures the patient is discharged at a later time

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · hours
Time to Eligibility for Home Discharge
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Eligibility for Home Discharge3.021 ± 1.0123.545 ± 1.2813.530 ± 0.887
SecondaryTime to First Spontaneous Urine Voiding

Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · hours
Time to First Spontaneous Urine Voiding
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to First Spontaneous Urine Voiding2.530 ± 0.7613.361 ± 1.1203.067 ± 0.755
SecondaryTime to First Post-operative Analgesia

Time from spinal injection (time 0 h) to first post-operative analgesia

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · hours
Time to First Post-operative Analgesia
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to First Post-operative Analgesia8.186 ± 10.8152.928 ± 1.2282.988 ± 1.167
SecondaryTime to Administration of Rescue Anaesthesia or Rescue Analgesia
Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · hours
Time to Administration of Rescue Anaesthesia or Rescue Analgesia
hours3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Time to Administration of Rescue Anaesthesia or Rescue Analgesia0.717 ± 0.3970.315 ± 0.0490 ± 0
SecondaryConcentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
Time frame:
at pre-dose, 5, 10, 30 and 60 min after spinal puncture
Reported as:
Mean · minutes
Concentration of 2-chloro-4-aminobenzoic Acid (CABA) in Plasma
minutes3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
5 minutes post-dose16.127 ± 20.10820.411 ± 23.03724.887 ± 20.340
10 minutes post-dose41.440 ± 31.77838.851 ± 25.49275.833 ± 67.635
30 minutes post-dose57.459 ± 43.77367.180 ± 36.89997.647 ± 61.704
60 minutes post-dose47.020 ± 41.38153.093 ± 31.80378.380 ± 48.403
SecondaryExcretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine

Time period from spinal injection ( time 0 h) to the first time when the patient can pass urine unassisted

Time frame:
at the time of first urine voiding post surgery
Reported as:
Mean · ng/mL
Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine
ng/mL3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Excretion of 2-chloro-4-aminobenzoic Acid (CABA) in Urine1217.7 ± 627.81827.9 ± 904.12103.5 ± 1537.5
SecondaryTreatment-emergent Adverse Events (TEAEs)

All AEs occurring or worsening after the dose of IMP

Time frame:
Up to Day 6 +/- 1 after spinal puncture
Reported as:
Number · participants
Treatment-emergent Adverse Events (TEAEs)
participants3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Procedural pain141313
Injection site pain233
nausea011
diarrhea010
vomiting010
bradycardia010
SecondaryTransient Neurological Symptoms (TNS)
Time frame:
Up to Day 6 +/- 1 after spinal puncture
Reported as:
Number · participants
Transient Neurological Symptoms (TNS)
participants3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
day 2000
day 7000
SecondaryPain Assessment at the Site of Injection and at the Site of Surgery

Number of patients with pain at the site of injection and at the site of surgery

Time frame:
Up to Day 6 +/- 1 after spinal puncture
Reported as:
Number · participants
Pain Assessment at the Site of Injection and at the Site of Surgery
participants3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Immediately after regression of spinal block000
discharge000
day 2141515
day 7151515
SecondaryHeart Rate

The following normal ranges Heart Rate parameters will be used: 50-90 beats/min

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · beats/min
Heart Rate
beats/min3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
screening62.2 ± 8.567.5 ± 11.470.7 ± 8.6
baseline63.1 ± 9.471 ± 1471.7 ± 9.2
discharge64.9 ± 766.9 ± 1067 ± 8
SecondaryBlood Pressure

The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · mmHg
Blood Pressure
mmHg3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Systolic Blood Pressure screening120 ± 12.9126 ± 21.74121.6 ± 9.1
Systolic Blood Pressure baseline116.9 ± 10.5127.9 ± 19.7125.5 ± 14.1
Systolic Blood Pressure discharge116.9 ± 10.9124.7 ± 14.7121.7 ± 8.9
Diastolic Blood Pressure screening81.5 ± 12.178.9 ± 11.980.5 ± 9.9
Diastolic Blood Pressure baseline74.5 ± 10.379.8 ± 10.979.1 ± 13.3
Diastolic Blood Pressure discharge75.5 ± 12.279 ± 8.182 ± 9.5
SecondarySpO2

The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%

Time frame:
Expected up to 24 hrs post surgery
Reported as:
Mean · percentage
SpO2
percentage3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
screening99.7 ± 0.9699.13 ± 1.2598.53 ± 1.36
baseline99.4 ± 0.9199.13 ± 0.8398.53 ± 1.51
discharge99.33 ± 0.7299.33 ± 0.9099 ± 1.07

Adverse events

Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mL Chloroprocaine HCl 1%—0/15 (0%)15/15 (100%)
4 mL Chloroprocaine HCl 1%—0/15 (0%)13/15 (86.7%)
5 mL Chloroprocaine HCl 1%—0/15 (0%)13/15 (86.7%)
Most frequent other events
Most frequent other events
Event3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%
Procedural painInjury, poisoning and procedural complications14/1513/1513/15
injection site painGeneral disorders2/153/153/15
nauseaGastrointestinal disorders0/151/151/15
diarrhoaeGastrointestinal disorders0/151/150/15
vomitingGastrointestinal disorders0/151/150/15
bradycardiaCardiac disorders0/151/150/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%Total
<=18 years0.00.00.00
Between 18 and 65 years15151545
>=65 years0000
Age, Continuous
Age, Continuous(years)3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%Total
Mean41.0 ± 11.739.4 ± 12.541.5 ± 13.940.6 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%Total
Female66618
Male99927
Region of Enrollment
Region of Enrollment(participants)3 mL Chloroprocaine HCl 1%4 mL Chloroprocaine HCl 1%5 mL Chloroprocaine HCl 1%Total
Italy15151545
08

Study locations

1 site
  • Stefano Bonarelli
    Bologna, 40136, Italy
09

References and documents

Publications

  • Ghisi D, Boschetto G, Spinelli AM, Giannone S, Frugiuele J, Ciccarello M, Bonarelli S. Spinal anaesthesia with Chloroprocaine HCl 1% for elective lower limb procedures of short duration: a prospective, randomised, observer-blind study in adult patients. BMC Anesthesiol. 2021 Feb 20;21(1):58. doi: 10.1186/s12871-021-01279-9. PubMed 33610175 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Nov 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2021, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2015
First posted
Jun 25, 2015
Start
Jun 2015
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Results first posted
May 18, 2021
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02481505
Lead sponsor
Sintetica SA
Collaborators
Cross S.A.
Responsible party
Sponsor
First posted
Jun 25, 2015
Start date
Jun 2015
Primary completion
Nov 2015
Completion
Nov 2015
Results posted
May 18, 2021
Last update
May 18, 2021

Study contacts

Stefano MD Bonarelli
principal investigator · Istituto Ortopedico Rizzoli, SC Anestesia e Terapia Intensiva post-operatoria e del dolore IOR-IRCCS

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chloroprocaine

Start the discussion